How PD-L1 Biomarker Test Results Impact Clinical Management of Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.
Listen as Dr Agarwala presents how developments in personalized medicine will impact and change the way drugs are developed and approved.
John Hennessy provides a few benefits of personalized medicine as it effects the ability to make better treatment choices earlier rather than later